NEWS

Impactful technology

1_US5SNOIYRFqJui28cWXIrQ.jpg
14351%2520Borrelia%2520recurrentis_edite
November 2022

 

HelixBind selected as Phase 1 winner of the LymeX Diagnostics Prize competition from

the U.S. Department of Health and Human Services and the Steven & Alexandra Cohen Foundation.

25SCI-SEPSIS-articleLarge.jpg
June 2021

HelixBind Awarded $3MM NIH Grant to Support Testing of Its

RaPID Diagnostic Platform for Invasive Infections Associated with Sepsis

Closeup of a Petri Dish
AUGUST 2020

 

FDA Grants HelixBind Breakthrough Device Designation for RaPID Sepsis Test.

14351%2520Borrelia%2520recurrentis_edite
JULY 2020

 

HelixBind awarded $3M Grant from NIH for New Rapid Test for the Early Detection of Lyme Disease.

Test Tubes
JUNE 2020

 

HelixBind awarded $3M Grant from NIH and expands Clinical Advisory Board to accelerate development of its diagnostic platform for invasive infections.

petri-dish.jpg
December 2019

 

HelixBind awarded $4M of additional funding by CARB-X to continue development of RaPID diagnostic platform.

images.jpg
MARCH 2018

 

HelixBind awarded up to $2M from CARB- X to combat the rise of antimicrobial resistant pathogens.

25SCI-SEPSIS-articleLarge.jpg
SEPTEMBER 2017

HelixBind closes $3M in Series-A financing

image-asset.jpeg
AUGUST 2017

HelixBind awarded a $2M Phase II SBIR from the National Institutes of Health (NIH) to further development of a culture-free, sample-to-answer test for detecting and identifying microbial pathogens prevalent in neonatal sepsis.

Science Lab
APRIL 2017

USPTO issues HelixBind patent US 14/402,028 covering methods and compositions of matter for diagnosing sepsis

ACEP_0317_pg1a_slider.png
AUGUST 2016

HelixBind awarded a $2.4M Direct-to-Phase II SBIR from the National Institutes of Health (NIH) to automate its sample-to-answer test for discriminating among bacterial pathogens

image-asset.jpeg
MARCH 2016

HelixBind published its work, completed in collaboration with Tufts Medical Center and Sloan Memorial Kettering Cancer Center demonstrating successful implementation of its novel sample-to-answer Core Pathogen Identification (C/PID) platform for identifying bloodstream infections directly from patient specimens in under 2.5 hours.

Test Tubes
JULY 2015

HelixBind awarded $1.5M Phase II SBIR from the National Institutes of Health (NIH)

Helixbind.png
MARCH 2014

HelixBind closes $1.65M seed financing